Ligand Pharma (LGND) PT Lowered to $135 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Ligand Pharma (LGND) PT Lowered to $135 at H.C. Wainwright
October 24, 2022 5:00 PM EDT
APAC Shareholder Approval Obtained, Closing Scheduled for November 1, 2022
Ligand Regular Way and Ex-Distribution and OmniAb When-Issued Set to Begin Trading on October 25, 2022
SAN DIEGO--(BUSINESS WIRE)--
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the business combination (Business Combination) of Avista Public Acquisition Corp. II (APAC) (NASDAQ: AHPA) and OmniAb, Inc. (OmniAb), was approved by APAC shareholders in a vote held this morning, with 96% of the shares represented in person, virtually or by proxy voting in favor of the combination. Based on actual... More
October 21, 2022 10:00 AM EDT
COLUMBUS, Ohio, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today shared additional findings from its Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE 1) Phase 2 study during the 4th Annual Congress of the International Society of Liquid Biopsy (ISLB) in Miami.
Initial results from the open-label (NCT03781063) study assessing the efficacy and safety of Sermonixs lead development candidate, oral lasofoxifene, versus the current standard of care, intramuscular fulvestrant, in postmenopausal women with locally advanced or metastatic ER+/HER2-... More
